Georges Azzi: Medical Doctor MD. Hematology/Oncology
Miami, FL
Joined May 2007
- Tweets6.3K
- Following4.6K
- Followers2.4K
- Likes1.8K
Georges Azzi retweeted
Today we approved a first-in-class targeted therapy for metastatic pancreatic cancer – one of the hardest cancers to treat. Today’s approval provides a critical new treatment for patients who’ve had very few options. fda.gov/news-events/press-an…
Georges Azzi retweeted
New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body.
nature.com/articles/s41586-0…
Georges Azzi retweeted
If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT.
Co-PI: Abhishek Tripathi, MD @cityofhope
swog.org/clinical-trials/S24…
Georges Azzi retweeted
This is huge. Congrats to @tompowles1 @BartsECMC & team who took this from a brilliant paper in @Nature in 2021 to a paradigm-shifting + P3 trial. @BladderCancerUS @IBCG_BladderCA
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers!
@NateraGenetics @tompowles1 @Roche
natera.com/company/news/imvi…
Georges Azzi retweeted
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers!
@NateraGenetics @tompowles1 @Roche
natera.com/company/news/imvi… – at Boston, MA
Georges Azzi retweeted
The Peptide Craze
I review what we know about 15 different injectable peptides being used without FDA approval or off-label, and NAD+
In the new Ground Truths; free, open-access
Georges Azzi retweeted
1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber
nature.com/articles/s41586-0…
@DanaFarber_GU @OncoAlert @DFCI_NeoVax
🧵 Breakthrough in Early-Stage Lung Adenocarcinoma Recurrence Detection Using ctDNA
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma | Nature Medicine nature.com/articles/s41591-0…
8/9 In early-stage NSCLC, where recurrence risk is high despite surgery, personalized ctDNA assays like NeXT Personal are essential for precision medicine. This is a giant leap toward better patient outcomes and more efficient trials. 🧬
9/9 Stay tuned as these advancements bridge the gap between research and routine care, paving the way for ctDNA to become a gold standard in oncology.
📖 Read the full study in Nature Medicine: doi.org/10.1038/s41591-024-0…
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma | Nature Medicine nature.com/articles/s41591-0…
Georges Azzi retweeted
Liquid biopsy is here to stay!
Clearance of ctDNA in neoadjuvant phase is associated with improved outcomes to durva + tremlo + EV in cis-ineligible pts with MIBC
# ESMO24
@OncoAlert
Georges Azzi retweeted
Building a clinical/genetic ctDNA prognostic model for OS in CRPC #ASCO24 . Including CtDNA improves accuracy compared clinical factors alone. Adding specific AR alterations is even better
